DiaMedica Therapeutics Inc. Operating Cash Flow
DiaMedica Therapeutics Inc. (DMAC) reported Operating Cash Flow of -$17.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- DiaMedica Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$8.11M.
- DiaMedica Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$9.08M.
- DiaMedica Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.76M.
- DiaMedica Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.55M.
- DiaMedica Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$29.06M.
- DiaMedica Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$22.08M.
- DiaMedica Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$18.73M.
- DiaMedica Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$11.51M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$17.20M 10-Q · filed 2026-08-10 | -$24.96M derived: sum of 3 quarters · filed 2026-08-10 | -$31.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$9.08M 10-Q · filed 2026-05-06 | -$16.85M derived: sum of 2 quarters · filed 2026-05-06 | -$23.40M derived: sum of 3 quarters · filed 2026-05-06 | -$31.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$14.31M derived: sum of 2 quarters · filed 2026-03-30 | -$21.91M derived: sum of 3 quarters · filed 2026-08-10 | -$29.06M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$6.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$14.15M derived: sum of 2 quarters · filed 2026-08-10 | -$21.30M 10-Q · filed 2025-11-12 | -$27.73M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$7.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$14.75M 10-Q · filed 2026-08-10 | -$21.18M derived: sum of 3 quarters · filed 2026-08-10 | -$25.65M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$7.15M 10-Q · filed 2026-05-06 | -$13.58M derived: sum of 2 quarters · filed 2026-05-06 | -$18.05M derived: sum of 3 quarters · filed 2026-05-06 | -$22.57M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$6.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$10.90M derived: sum of 2 quarters · filed 2026-03-30 | -$15.42M derived: sum of 3 quarters · filed 2026-03-30 | -$22.08M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$8.99M derived: sum of 2 quarters · filed 2025-11-12 | -$15.64M 10-Q · filed 2025-11-12 | -$19.45M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$4.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$11.17M 10-Q · filed 2025-08-12 | -$14.98M derived: sum of 3 quarters · filed 2025-08-12 | -$19.78M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$6.65M 10-Q · filed 2025-05-13 | -$10.46M derived: sum of 2 quarters · filed 2025-05-13 | -$15.26M derived: sum of 3 quarters · filed 2025-05-13 | -$20.29M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$8.61M derived: sum of 2 quarters · filed 2025-03-17 | -$13.64M derived: sum of 3 quarters · filed 2025-03-17 | -$18.73M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$9.83M derived: sum of 2 quarters · filed 2024-11-13 | -$14.92M 10-Q · filed 2024-11-13 | -$17.68M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$10.12M 10-Q · filed 2024-08-07 | -$12.88M derived: sum of 3 quarters · filed 2024-08-07 | -$15.25M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$5.09M 10-Q · filed 2024-05-08 | -$7.86M derived: sum of 2 quarters · filed 2024-05-08 | -$10.22M derived: sum of 3 quarters · filed 2024-05-08 | -$12.71M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$5.13M derived: sum of 2 quarters · filed 2024-03-19 | -$7.62M derived: sum of 3 quarters · filed 2024-03-19 | -$11.51M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$4.86M derived: sum of 2 quarters · filed 2023-11-13 | -$8.74M 10-Q · filed 2023-11-13 | -$11.55M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$6.38M 10-Q · filed 2023-08-14 | -$9.19M derived: sum of 3 quarters · filed 2023-08-14 | -$12.23M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$3.89M 10-Q · filed 2023-05-15 | -$6.69M derived: sum of 2 quarters · filed 2023-05-15 | -$9.74M derived: sum of 3 quarters · filed 2023-05-15 | -$11.83M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$5.85M derived: sum of 2 quarters · filed 2023-03-28 | -$7.94M derived: sum of 3 quarters · filed 2023-03-28 | -$12.25M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$3.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$5.13M derived: sum of 2 quarters · filed 2022-11-09 | -$9.45M 10-Q · filed 2022-11-09 | -$12.46M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$6.40M 10-Q · filed 2022-08-11 | -$9.42M derived: sum of 3 quarters · filed 2022-08-11 | -$11.77M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$4.31M 10-Q · filed 2022-05-04 | -$7.33M derived: sum of 2 quarters · filed 2022-05-04 | -$9.68M derived: sum of 3 quarters · filed 2022-05-04 | -$10.52M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$5.36M derived: sum of 2 quarters · filed 2022-03-14 | -$6.21M derived: sum of 3 quarters · filed 2022-03-14 | -$9.19M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$3.19M derived: sum of 2 quarters · filed 2021-11-10 | -$6.17M 10-Q · filed 2021-11-10 | -$8.03M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$844.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$3.82M 10-Q · filed 2021-08-11 | -$5.69M derived: sum of 3 quarters · filed 2021-08-11 | -$6.92M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$2.98M 10-Q · filed 2021-05-05 | -$4.84M derived: sum of 2 quarters · filed 2021-05-05 | -$6.08M derived: sum of 3 quarters · filed 2021-05-05 | -$8.95M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$3.10M derived: sum of 2 quarters · filed 2021-03-10 | -$5.97M derived: sum of 3 quarters · filed 2021-03-10 | -$9.10M 10-K · filed 2021-03-10 |
| 2019-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$4.10M derived: sum of 2 quarters · filed 2020-11-04 | -$7.24M 10-Q · filed 2020-11-04 | -$9.14M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$6.00M 10-Q · filed 2020-08-11 | -$7.91M derived: sum of 3 quarters · filed 2020-08-11 | -$9.74M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$3.13M 10-Q · filed 2020-05-13 | -$5.03M derived: sum of 2 quarters · filed 2020-05-13 | -$6.87M derived: sum of 3 quarters · filed 2020-05-13 | -$7.89M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | -$3.74M derived: sum of 2 quarters · filed 2020-03-23 | -$4.76M derived: sum of 3 quarters · filed 2020-03-23 | -$5.70M 10-K · filed 2020-03-23 |
| 2018-09-30 | -$1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$2.86M derived: sum of 2 quarters · filed 2019-11-13 | -$3.80M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$1.96M 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | -$935.00K 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | -$3.90M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |